Nuzzo Carmen, Zeuli Massimo, Ferraresi Virginia, Ciccarese Mariangela, Pelligrini Domenica, Cognetti Francesco
Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy.
Anticancer Res. 2008 Mar-Apr;28(2B):1429-31.
The treatment of disseminated melanoma is inadequate. The most active single agents provide brief objective response in 20% of patients, while the combination chemotherapy improves response rates without any apparent survival benefit. Median overall survival is, in fact, 7-9 months and 5 year survival is approximately 6%. Metastatic melanoma with a localization of the disease in the liver and brain are categorized as M1c and have the worst prognosis. Here we describe the history, treatment and favourable clinical outcome in a young man with liver and resected brain metastases who obtained complete remission for 6 years since chemotherapy with dacarbazine, cisplatin and vinblastine.
播散性黑色素瘤的治疗方法并不完善。最有效的单一药物仅能使20%的患者获得短暂的客观缓解，而联合化疗虽能提高缓解率，但对生存率并无明显益处。事实上，患者的中位总生存期为7 - 9个月，5年生存率约为6%。疾病定位在肝脏和脑的转移性黑色素瘤被归类为M1c，预后最差。在此，我们描述了一名患有肝脏和脑转移瘤的年轻男性患者的病史、治疗过程及良好的临床结局，该患者自接受达卡巴嗪、顺铂和长春碱化疗后已完全缓解6年。
